MeiraGTx Holdings PLC
MGTX7.430USD
+0.230+3.19%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
597.96MCap. mercado
PérdidaP/E TTM
Más Datos de MeiraGTx Holdings PLC Compañía
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Información de MeiraGTx Holdings PLC
Símbolo de cotizaciónMGTX
Nombre de la empresaMeiraGTx Holdings PLC
Fecha de salida a bolsaJun 08, 2018
Director ejecutivoForbes (Alexandria)
Número de empleados381
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 08
Dirección655 Third Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10017
Teléfono16468607985
Sitio Webhttps://meiragtx.com/
Símbolo de cotizaciónMGTX
Fecha de salida a bolsaJun 08, 2018
Director ejecutivoForbes (Alexandria)
Ejecutivos de MeiraGTx Holdings PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
52.08K
+25930.00%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Otro
53.54%
Accionistas
Accionistas
Proporción
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Otro
53.54%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
26.91%
Corporation
16.02%
Private Equity
12.77%
Venture Capital
8.29%
Investment Advisor
7.72%
Individual Investor
4.74%
Investment Advisor/Hedge Fund
4.39%
Research Firm
2.26%
Pension Fund
0.09%
Otro
16.80%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
236
50.32M
62.51%
-4.52M
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sanofi SA
12.20M
15.15%
--
--
Sep 30, 2025
Perceptive Advisors LLC
10.28M
12.77%
-2.35M
-18.57%
Dec 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.25%
--
--
Sep 30, 2025
Adage Capital Management, L.P.
4.18M
5.2%
-1.85M
-30.66%
Sep 30, 2025
Prosight Capital
4.09M
5.08%
-497.91K
-10.85%
Sep 30, 2025
Rubric Capital Management LP
3.73M
4.63%
--
--
Sep 30, 2025
683 Capital Management LLC
2.63M
3.26%
-65.00K
-2.42%
Sep 30, 2025
Millennium Management LLC
2.56M
3.18%
+1.78M
+226.16%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
2.97%
-94.99K
-3.82%
Sep 30, 2025
J. Goldman & Co., L.P.
1.80M
2.24%
-243.64K
-11.92%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Goldman Sachs Innovate Equity ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Ver más
iShares Micro-Cap ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.07%
Invesco Nasdaq Biotechnology ETF
Proporción0.07%
Goldman Sachs Innovate Equity ETF
Proporción0.06%
Vanguard US Momentum Factor ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.02%
SPDR S&P International Small Cap ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
